Wolcott D L, Marsh J T, La Rue A, Carr C, Nissenson A R
Department of Medicine, UCLA School of Medicine 90024.
Am J Kidney Dis. 1989 Dec;14(6):478-85. doi: 10.1016/s0272-6386(89)80148-9.
Medical, psychological, and social adaptation (quality of life) as well as cognitive function were studied in 15 chronic stable hemodialysis patients before the onset of treatment with recombinant human erythropoietin (r-HuEPO), 1 month after stabilization of normal hematocrit levels, and 10 to 15 months after treatment onset. After r-HuEPO treatment, subjects had significantly higher hematocrits, markedly improved energy levels, and marginally improved global health. r-HuEPO treatment was also associated with progressively decreased levels of subject mood disturbance and dialysis-related stresses. Subjects had no increased participation in paid employment and only minimally increased participation in social and leisure activities at posttreatment data points. There was no significant improvement in cognitive function after treatment. r-HuEPO treatment appears to be associated with higher energy levels, significant psychological benefits, and minimal improvements in social adaptation. The effects on cognitive function merit further study.
对15例慢性稳定血液透析患者在使用重组人促红细胞生成素（r-HuEPO）治疗前、血细胞比容水平稳定正常1个月后以及治疗开始10至15个月后，研究了其医学、心理和社会适应性（生活质量）以及认知功能。r-HuEPO治疗后，受试者的血细胞比容显著升高，能量水平明显改善，整体健康状况略有改善。r-HuEPO治疗还与受试者情绪障碍和透析相关应激水平的逐渐降低有关。在治疗后的数据点，受试者从事有偿工作的参与度没有增加，参与社会和休闲活动的参与度仅略有增加。治疗后认知功能没有显著改善。r-HuEPO治疗似乎与更高的能量水平、显著的心理益处以及社会适应性的最小改善有关。对认知功能的影响值得进一步研究。
